Heidi is a strategic advisor and collaborative leader in intellectual property law, with over 20 years of experience guiding pharmaceutical, biotechnology, and chemical companies—from innovative startups to large enterprises -public and private—through the development, protection and leveraging of high-value patent portfolios.

Heidi partners closely with clients and cross-disciplinary teams to craft tailored IP strategies that support scientific advancement, business growth, and long-term market success. With a Ph.D. in chemistry and a deep technical background in biochemistry, she offers particular expertise in areas including small molecule pharmaceuticals, nucleic acid therapeutics, drug conjugates, and complex organic and organometallic chemistry.

Known for her practical insight and clear communication, Heidi advises on patent acquisition, portfolio management, FDA submissions, freedom-to-operate and invalidity analyses, and IP risk mitigation. She also leads strategic IP due diligence efforts for investors and companies involved in financings, partnerships, and M&A transactions.

Heidi believes in building lasting relationships with clients and colleagues alike, fostering a solutions-driven environment. Her vision is to help life sciences companies unlock the full value of their innovation by aligning IP strategy with company goals and business objectives—domestically and on the global stage.

She is recognized by Chambers USA, IAM Patent 1000, and LMG Life Sciences for her excellence in patent law and her leadership in the life sciences IP space.